Abstract
AGC will invest a total of almost $20 million in biologics contract manufacturing facilities in the US and Denmark. The Japanese firm will add a 500 L mammalian cell bioreactor in Seattle and a purification line in Copenhagen. The projects are set to be completed next year. AGC, the former Asahi Glass, got the facilities in 2017, when it bought the Danish firm CMC Biologics as part of a push into the life sciences.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
